L-Carnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE−/− transgenic mice expressing CETP
2015/11/04 by Heidi L. Collins, Denise Drazul‐Schrader, Denise Drazul-Schrader +8 · 28 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Metabolism and Genetic Disorders #Folate and B Vitamins Research #Gut microbiota and health
paper · doi:10.1016/j.atherosclerosis.2015.10.108
Abstract
OBJECTIVE: Dietary l-carnitine can be metabolized by intestinal microbiota to trimethylamine, which is absorbed by the gut and further oxidized to trimethylamine N-oxide (TMAO) in the liver. TMAO plasma levels have been associated with atherosclerosis development in ApoE(-/-) mice. To better understand the mechanisms behind this association, we conducted in vitro and in vivo studies looking at the effect of TMAO on different steps of atherosclerotic disease progression. METHODS: J774 mouse macrophage cells were used to evaluate the effect of TMAO on foam cell formation. Male ApoE(-/-) mice transfected with human cholesteryl ester transfer protein (hCETP) were fed l-carnitine and/or methimazole, a flavin monooxygenase 3 (FMO3) inhibitor that prevents the formation of TMAO. Following 12 week treatment, l-carnitine and TMAO plasma levels, aortic lesion development, and lipid profiles were determined. RESULTS: TMAO at concentrations up to 10-fold the Cmax reported in humans did not affect in vitro foam cell formation. In ApoE(-/-)mice expressing hCETP, high doses of l-carnitine resulted in a significant increase in plasma TMAO levels. Surprisingly, and independently from treatment group, TMAO levels inversely correlated with aortic lesion size in both aortic root and thoracic aorta. High TMAO levels were found to significantly correlate with smaller aortic lesion area. Plasma lipid and lipoprotein levels did not change with treatment nor with TMAO levels, suggesting that the observed effects on lesion area were independent from lipid changes. CONCLUSION: These findings suggest that TMAO slows aortic lesion formation in this mouse model and may have a protective effect against atherosclerosis development in humans.
Cited by
- TrimethylamineN-Oxide, the Microbiome, and Heart and Kidney Disease
- Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson's disease
- Gut microbiota in human metabolic health and disease
- Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. [europepmc]
- Human risk of diseases associated with red meat intake: Analysis of current theories and proposed role for metabolic incorporation of a non-human sialic acid. [europepmc]
- Trimethylamine N-Oxide: The Good, the Bad and the Unknown. [europepmc]
- Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System. [europepmc]
- Microbial modulation of cardiovascular disease. [europepmc]
- Implication of gut microbiota metabolites in cardiovascular and metabolic diseases. [europepmc]
- Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target. [europepmc]
- The Role of Gut Microbiota in Atherosclerosis and Hypertension. [europepmc]
- Trimethylamine N -Oxide: A Link among Diet, Gut Microbiota, Gene Regulation of Liver and Intestine Cholesterol Homeostasis and HDL Function. [europepmc]
- Dietary metabolism, the gut microbiome, and heart failure. [europepmc]
- Trimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism. [europepmc]
- Choline: The Underconsumed and Underappreciated Essential Nutrient. [europepmc]
- Gut Microbiota and Ischemic Stroke: The Role of Trimethylamine N-Oxide. [europepmc]
- Dietary lipids, gut microbiota and lipid metabolism. [europepmc]
- Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target. [europepmc]
- Trimethylamine-N-oxide has prognostic value in coronary heart disease: a meta-analysis and dose-response analysis. [europepmc]
- Trimethylamine N-Oxide Generated by the Gut Microbiota Is Associated with Vascular Inflammation: New Insights into Atherosclerosis. [europepmc]
- Fecal Microbiota Transplantation in Neurological Disorders. [europepmc]
- Trimethylamine N-Oxide in Relation to Cardiometabolic Health-Cause or Effect? [europepmc]
- Role of Gut Microbiota and Their Metabolites on Atherosclerosis, Hypertension and Human Blood Platelet Function: A Review. [europepmc]
- The Role of Gut Microbiota on Cholesterol Metabolism in Atherosclerosis. [europepmc]
- How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. [europepmc]
- Regulation of blood-brain barrier integrity by microbiome-associated methylamines and cognition by trimethylamine N-oxide. [europepmc]
- Microbiota-derived metabolites as drivers of gut-brain communication. [europepmc]
- Gut Microbiota-Derived TMAO: A Causal Factor Promoting Atherosclerotic Cardiovascular Disease? [europepmc]
Related